Axsome Therapeutics (AXSM) Competitors

$230.62 +3.95 (+1.74%)

Closing price 04:00 PM Eastern

Extended Trading

$230.25 -0.37 (-0.16%)

As of 05:58 PM Eastern

AXSM vs. JAZZ, TEVA, ONC, RVMD, and INSM

Should you buy Axsome Therapeutics stock or one of its competitors? MarketBeat compares Axsome Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Axsome Therapeutics include Jazz Pharmaceuticals (JAZZ), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Revolution Medicines (RVMD), and Insmed (INSM). These companies are all part of the "medical" sector.

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Jazz Pharmaceuticals has a net margin of 0.66% compared to Axsome Therapeutics' net margin of -26.59%. Jazz Pharmaceuticals' return on equity of 14.56% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	0.66%	14.56%	5.25%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 4.3% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Jazz Pharmaceuticals has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

Jazz Pharmaceuticals presently has a consensus price target of $238.00, suggesting a potential downside of 0.42%. Axsome Therapeutics has a consensus price target of $251.26, suggesting a potential upside of 8.95%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

Axsome Therapeutics has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.51	-$356.15M	-$0.02	N/A
Axsome Therapeutics	$638.50M	18.59	-$183.17M	-$3.73	N/A

In the previous week, Jazz Pharmaceuticals had 10 more articles in the media than Axsome Therapeutics. MarketBeat recorded 12 mentions for Jazz Pharmaceuticals and 2 mentions for Axsome Therapeutics. Jazz Pharmaceuticals' average media sentiment score of 0.75 beat Axsome Therapeutics' score of 0.02 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Jazz Pharmaceuticals and Axsome Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Axsome Therapeutics compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Teva Pharmaceutical Industries has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.29	$1.41B	$1.33	25.80
Axsome Therapeutics	$638.50M	18.59	-$183.17M	-$3.73	N/A

Teva Pharmaceutical Industries has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 19 more articles in the media than Axsome Therapeutics. MarketBeat recorded 21 mentions for Teva Pharmaceutical Industries and 2 mentions for Axsome Therapeutics. Teva Pharmaceutical Industries' average media sentiment score of 0.89 beat Axsome Therapeutics' score of 0.02 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	12 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Teva Pharmaceutical Industries currently has a consensus target price of $41.78, indicating a potential upside of 21.75%. Axsome Therapeutics has a consensus target price of $251.26, indicating a potential upside of 8.95%. Given Teva Pharmaceutical Industries' higher possible upside, equities analysts clearly believe Teva Pharmaceutical Industries is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Axsome Therapeutics' net margin of -26.59%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Summary

Teva Pharmaceutical Industries beats Axsome Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to BeOne Medicines?

Axsome Therapeutics (NASDAQ:AXSM) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Axsome Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

BeOne Medicines has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	18.59	-$183.17M	-$3.73	N/A
BeOne Medicines	$5.34B	6.34	$286.93M	$4.47	69.07

Axsome Therapeutics currently has a consensus target price of $251.26, indicating a potential upside of 8.95%. BeOne Medicines has a consensus target price of $389.15, indicating a potential upside of 26.05%. Given BeOne Medicines' higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, BeOne Medicines had 2 more articles in the media than Axsome Therapeutics. MarketBeat recorded 4 mentions for BeOne Medicines and 2 mentions for Axsome Therapeutics. BeOne Medicines' average media sentiment score of 0.59 beat Axsome Therapeutics' score of 0.02 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BeOne Medicines has a net margin of 8.94% compared to Axsome Therapeutics' net margin of -26.59%. BeOne Medicines' return on equity of 12.06% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
BeOne Medicines	8.94%	12.06%	6.69%

Summary

BeOne Medicines beats Axsome Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Axsome Therapeutics compare to Revolution Medicines?

Axsome Therapeutics (NASDAQ:AXSM) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Revolution Medicines has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Revolution Medicines' return on equity of -83.22% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Revolution Medicines	N/A	-83.22%	-59.06%

Axsome Therapeutics currently has a consensus target price of $251.26, indicating a potential upside of 8.95%. Revolution Medicines has a consensus target price of $108.88, indicating a potential downside of 27.58%. Given Axsome Therapeutics' higher probable upside, equities analysts plainly believe Axsome Therapeutics is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Revolution Medicines	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	3.05

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 8.2% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Axsome Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

Axsome Therapeutics has higher revenue and earnings than Revolution Medicines. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	18.59	-$183.17M	-$3.73	N/A
Revolution Medicines	$11.58M	2,759.94	-$1.13B	-$7.07	N/A

In the previous week, Revolution Medicines had 6 more articles in the media than Axsome Therapeutics. MarketBeat recorded 8 mentions for Revolution Medicines and 2 mentions for Axsome Therapeutics. Revolution Medicines' average media sentiment score of 0.72 beat Axsome Therapeutics' score of 0.02 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Revolution Medicines beats Axsome Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to Insmed?

Insmed (NASDAQ:INSM) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Insmed has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market.

In the previous week, Insmed had 11 more articles in the media than Axsome Therapeutics. MarketBeat recorded 13 mentions for Insmed and 2 mentions for Axsome Therapeutics. Insmed's average media sentiment score of 1.35 beat Axsome Therapeutics' score of 0.02 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Axsome Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Insmed presently has a consensus price target of $210.95, indicating a potential upside of 95.49%. Axsome Therapeutics has a consensus price target of $251.26, indicating a potential upside of 8.95%. Given Insmed's stronger consensus rating and higher possible upside, equities research analysts clearly believe Insmed is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

Axsome Therapeutics has a net margin of -26.59% compared to Insmed's net margin of -144.44%. Insmed's return on equity of -130.11% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

81.5% of Axsome Therapeutics shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Axsome Therapeutics has higher revenue and earnings than Insmed. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	38.57	-$1.28B	-$5.75	N/A
Axsome Therapeutics	$638.50M	18.59	-$183.17M	-$3.73	N/A

Summary

Insmed beats Axsome Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Axsome Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AXSM vs. The Competition

Export

Metric	Axsome Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.66B	$3.27B	$6.30B	$12.12B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-61.83	10.41	17.81	22.71
Price / Sales	18.59	272.00	529.98	73.50
Price / Cash	N/A	125.35	43.18	55.00
Price / Book	217.57	6.81	9.91	6.94
Net Income	-$183.17M	$24.18M	$3.55B	$335.25M
7 Day Performance	-2.00%	-0.25%	-0.30%	-0.70%
1 Month Performance	22.22%	-4.58%	-2.34%	-0.90%
1 Year Performance	112.85%	55.65%	30.89%	29.67%

Axsome Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AXSM Axsome Therapeutics	2.3938 of 5 stars	$230.62 +1.7%	$251.26 +9.0%	+109.3%	$11.66B	$638.50M	N/A	380
JAZZ Jazz Pharmaceuticals	2.8458 of 5 stars	$229.55 +0.3%	$230.56 +0.4%	+116.3%	$14.35B	$4.27B	N/A	2,890	Analyst Upgrade
TEVA Teva Pharmaceutical Industries	4.5487 of 5 stars	$34.08 -0.6%	$41.78 +22.6%	+100.7%	$39.43B	$17.26B	25.62	33,950	Insider Trade
ONC BeOne Medicines	4.1417 of 5 stars	$293.09 -0.1%	$389.15 +32.8%	+27.3%	$32.18B	$5.34B	65.57	12,000
RVMD Revolution Medicines	2.4881 of 5 stars	$144.37 -0.9%	$108.88 -24.6%	+268.9%	$30.97B	$11.58M	N/A	250	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AXSM) was last updated on 5/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Axsome Therapeutics (AXSM) Competitors

AXSM vs. JAZZ, TEVA, ONC, RVMD, and INSM

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Summary

How does Axsome Therapeutics compare to Teva Pharmaceutical Industries?

Summary

How does Axsome Therapeutics compare to BeOne Medicines?

Summary

How does Axsome Therapeutics compare to Revolution Medicines?

Summary

How does Axsome Therapeutics compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXSM vs. The Competition

Axsome Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Axsome Therapeutics (AXSM) Competitors

AXSM vs. JAZZ, TEVA, ONC, RVMD, and INSM

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Is JAZZ or AXSM more profitable?

Do insiders and institutionals have more ownership in JAZZ or AXSM?

Which has more volatility & risk, JAZZ or AXSM?

Do analysts prefer JAZZ or AXSM?

Which has stronger earnings & valuation, JAZZ or AXSM?

Does the media favor JAZZ or AXSM?

Summary

How does Axsome Therapeutics compare to Teva Pharmaceutical Industries?

Which has higher valuation and earnings, TEVA or AXSM?

Which has more risk & volatility, TEVA or AXSM?

Does the media favor TEVA or AXSM?

Do insiders and institutionals have more ownership in TEVA or AXSM?

Do analysts rate TEVA or AXSM?

Is TEVA or AXSM more profitable?

Summary

How does Axsome Therapeutics compare to BeOne Medicines?

Which has more risk and volatility, AXSM or ONC?

Which has better valuation and earnings, AXSM or ONC?

Do analysts rate AXSM or ONC?

Does the media prefer AXSM or ONC?

Do insiders & institutionals believe in AXSM or ONC?

Is AXSM or ONC more profitable?

Summary

How does Axsome Therapeutics compare to Revolution Medicines?

Is AXSM or RVMD more profitable?

Do analysts prefer AXSM or RVMD?

Do institutionals and insiders have more ownership in AXSM or RVMD?

Which has more volatility & risk, AXSM or RVMD?

Which has preferable valuation and earnings, AXSM or RVMD?

Does the media favor AXSM or RVMD?

Summary

How does Axsome Therapeutics compare to Insmed?

Which has more volatility and risk, INSM or AXSM?

Does the media favor INSM or AXSM?

Do analysts prefer INSM or AXSM?

Is INSM or AXSM more profitable?

Do institutionals & insiders have more ownership in INSM or AXSM?

Which has stronger earnings & valuation, INSM or AXSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXSM vs. The Competition

Axsome Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools